Navigation Links
OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
Date:4/9/2009

BOTHELL, WA, and VANCOUVER, April 9 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI), announced today that it has been named the 2009 Life Sciences Company of the Year by LifeSciences British Columbia. This annual award is presented by LifeSciences British Columbia to recognize a local organization that has made outstanding contributions to the development of British Columbia's life sciences industry. This award recognizes a company for execution of business strategies, scientific excellence, leadership and vision and market position/opportunity. The organization also uses this award to increase public awareness and understanding of life sciences in the province.

"We are very pleased to be recognized for this award, especially in light of what was a particularly challenging economic environment in 2008," said Scott Cormack, President and CEO of OncoGenex. "For OncoGenex, 2008 was a tremendously active year as we took measures to prepare for the final stages of clinical development of our lead product candidate, OGX-011, for the treatment of cancer. We released Phase 2 clinical data showing a survival benefit in patients treated with OGX-011 and are working closely with the FDA to develop Phase 3 study designs and protocols defining a registration path for product approval. We also took measures to extend our cash runway, and we have been advancing discussions with potential development partners."

"There is no greater honour than to be recognized by one's peers," added Cormack. "I'd like to thank all the employees at OncoGenex, as this award was earned by each and every one of them through their dedication, hard work and loyalty."

About LifeSciences British Columbia

LifeSciences British Columbia supports and represents the biopharmaceutical, medical device, biopro
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... 20, 2014 MediVet America ... a groundbreaking surgery at the specialized Wolvega Horse Clinic. ... digital flexor tendon was ruptured 90% and her deep ... is a death sentence for a horse. , The ... cell treatments . This revolutionary regenerative option for ...
(Date:9/19/2014)... San Jose, California (PRWEB) September 19, 2014 ... – Nanotechnology and its potential to revolutionize the ... government agencies, multinational corporations and small start-ups. The ... government funded research projects largely due to the ... capital investments. Government budgets earmarked for this evolving ...
(Date:9/19/2014)... BioTech News Coverage: Progress made ... of studies and trials.  Companies in focus are: GenSpera ... LLY ), Gilead Sciences Inc. (NASDAQ: ... and Arena Pharmaceuticals Inc. (NASDAQ: ARNA) GenSpera, ... for the treatment of cancer, announced that the United ...
(Date:9/19/2014)... , September 19, 2014 The ... Spain , available today on PharmaBoardroom.com ... the Eurozone crisis that rocked the Spanish economy in 2009, ... Spanish pharma community has remained pragmatic in times of trouble. ... is still the fifth biggest European market, and the general ...
Breaking Biology Technology:World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 2World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3
... Aug. 30, 2011 Farmers in North Carolina will ... a partnership by Perdue AgriBusiness and Winston-Salem-based Technology Crops ... the crop looks identical to canola, but the oil ... applications, especially industrial uses.  Grown in trials in North ...
... Aug. 30, 2011 Amnis Corporation, a manufacturer of advanced ... acquired by EMD Millipore, the Life Science division of Merck ... and closing is expected to take place in the fourth ... disclosed. Amnis generated sales of USD 14 ...
... SANTA CLARA, Calif., Aug. 30, 2011 ProteinSimple today introduced ... Simple Western.  The Simple Western is a complete reinvention of ... protein research.  For the first time in 30 years, researchers ... analysis. The Western Blot was invented in ...
Cached Biology Technology:Perdue AgriBusiness and TCI Collaborate to Bring Profitable New Crop to North Carolina 2Perdue AgriBusiness and TCI Collaborate to Bring Profitable New Crop to North Carolina 3Perdue AgriBusiness and TCI Collaborate to Bring Profitable New Crop to North Carolina 4Amnis Acquired by EMD Millipore - Expands Growth Potential 2Amnis Acquired by EMD Millipore - Expands Growth Potential 3ProteinSimple Reinvents the Western Blot 2
(Date:9/18/2014)... spoken language is unique to humans. "The genetic changes ... human evolution to make this possible are largely unknown, ... have," says Wolfgang Enard, Professor of Anthropology and Human ... molecular biological basis of language Enard has now taken ... study, undertaken in collaboration with scientists at several universities, ...
(Date:9/18/2014)... Va.Sept. 18, 2014Many Americans across racial and ethnic ... greatest impact on their day-to-day life, more so ... hearing and speech (57% of African-Americans, 49% of ... Hispanics). When asked which disease or ailment is ... ranked first among African-Americans followed by AIDS/HIV. ...
(Date:9/18/2014)... cycles of carbon and nitrogen comprise all spheres ... environmental systems have caused imbalances and perturbations that ... (GHGs). Increased GHGs result in climate changes which ... oceans and the atmosphere. Understanding these feedback mechanisms ... of environmental science during the past three decades. ...
Breaking Biology News(10 mins):Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3Greenhouse gas research enters a new era 2
... who can,t tolerate the side effects of cholesterol-lowering drugs ... study by researchers from the Intermountain Heart Institute at ... found that pitavastatin, a newer cholesterol-lowering drug, may reduce ... in up to 68 percent of patients with high ...
... amount of nitrogen into urban watersheds, diminishing both ... many studies documenting the impacts of nitrogen on ... of leaky sewer systemsuntil now., Aging sewer systems ... urban watersheds, diminishing both the quality of water ...
... journals will join John Wiley & Sons, Inc., a ... technical, medical, and scholarly research; professional development; and education, ... Wiley from other publishers or self-publication, and 14 new ... joining Wiley represent relationships with over 30 societies and ...
Cached Biology News:Researchers find alternative cholesterol-lowering drug for patients who can't tolerate statins 2Pittsburgh's leaky faucet: How aging sewers are impacting urban watersheds 266 titles join Wiley's journal portfolio in 2013 2
... This book is unique in that ... techniques currently used in the diagnosis ... virus-specific antibodies and clinical virus isolates. ... blotting and hybridization procedures, PCR for ...
...
... PCR Purification Kits provide rapid and efficient ... PCR products, and salts from PCR products ... provides two Binding Buffer options for ... can be performed in either single column ...
... TOPO PCR Cloning Kit offers the ... (>=95%) cloning of blunt-end PCR products ... kit includes the linearized and topoisomerase ... bench-top ligations without ligase (1). The ...
Biology Products: